Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 naxitamab + GM-CSF in refractory or salvage-incomplete-response high-risk neuroblastoma
2017-001829-40Phase 2Unknown
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of naxitamab and sargramostim in neuroblastoma, sponsored by Y-mAbs Therapeutics, Inc. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
naxitamabsargramostim
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2017-001829-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001829-40.